Spinola Monica, Leoni Vera Piera, Tanuma Jun-Ichi, Pettinicchio Angela, Frattini Milo, Signoroni Stefano, Agresti Roberto, Giovanazzi Riccardo, Pilotti Silvana, Bertario Lucio, Ravagnani Fernando, Dragani Tommaso A
Department of Experimental Oncology, Istituto Nazionale Tumori, Via G. Venezian 1, 20133 Milan, Italy.
Oncol Rep. 2005 Aug;14(2):415-9.
A functional Gly388Arg variation in the FGFR4 gene has been reported to be associated with breast and colorectal cancer prognostic parameters. To further examine the functional role of this genetic polymorphism at the population level, we assessed the presence of the Arg388 allele in 142 breast carcinoma patients, 179 colorectal carcinoma patients and 220 general population controls with respect to an association with cancer prognosis and/or risk. No significant association with cancer risk, survival or any other prognostic parameters was observed in either breast or colorectal cancer. A pooled analysis of the present and published data on nodal status by FGFR4 genotypes revealed no association in either breast cancer [odds ratio (OR), 1.0; 95% confidence interval (CI), 0.7-1.4; 702 subjects] or colorectal cancer (OR, 1.4; 95% CI, 0.6-3.4; 260 cases). Thus, the FGFR4 polymorphism may not be relevant in predicting nodal involvement of breast cancer or colon cancer patients.
据报道，FGFR4基因中一种功能性的Gly388Arg变异与乳腺癌和结直肠癌的预后参数相关。为了在人群水平上进一步研究这种基因多态性的功能作用，我们评估了142例乳腺癌患者、179例结直肠癌患者和220例普通人群对照中Arg388等位基因的存在情况，以探讨其与癌症预后和/或风险的关联。在乳腺癌或结直肠癌中，均未观察到与癌症风险、生存率或任何其他预后参数有显著关联。对目前和已发表的FGFR4基因型与淋巴结状态数据进行的汇总分析显示，在乳腺癌（优势比（OR）为1.0；95%置信区间（CI）为0.7 - 1.4；702名受试者）或结直肠癌（OR为1.4；95% CI为0.6 - 3.4；260例）中均无关联。因此，FGFR4基因多态性可能与预测乳腺癌或结肠癌患者的淋巴结受累情况无关。
